Medco Research's Adenoscan approved May 18; Fujisawa will market product.
This article was originally published in The Gray Sheet
MEDCO RESEARCH ADENOSCAN APPROVED MAY 18 by FDA as an injectable coronary vasodilator to be used as "an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately" to undergo stress testing for diagnosis of coronary artery disease. The adenosine product is composed of the endogenous naturally occurring nucleoside 6-amino-9-beta-D-ribofuranosyl-9-H-purine. FDA deemed the product "approvable" April 18.
You may also be interested in...
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.